Explore growth-hormone signalling and cellular adaptation with two vials each of CJC-1295 with DAC, ipamorelin and MOTS-c. This collection brings growth-axis and mitochondrial research into one clearly specified selection.
CURATED INDIVIDUAL ITEMS · TEST / DEMOAT A GLANCE
Inside the stack
CJC-1295 with DAC
2 × 5 mg single vial · $149.99 CAD each
$299.98 CAD
CJC-1295 with DAC is a growth-hormone-releasing hormone analogue with a Drug Affinity Complex. Research examines prolonged GH and IGF-1 responses, making it of interest in growth-axis physiology.
GHRH signalling — The analogue engages the growth-hormone-releasing hormone pathway.
DAC modification — The Drug Affinity Complex distinguishes this long-acting identity from non-DAC materials.
Hormone endpoints — Reviewed human physiology studies measure GH and IGF-1 changes under controlled conditions.
Ipamorelin is a pentapeptide ghrelin-receptor agonist studied for growth-hormone release. It offers a distinct receptor pathway for exploring growth-axis signalling alongside GHRH analogues.
Ghrelin receptor — Its secretagogue identity centres on the ghrelin-receptor pathway.
Growth-hormone release — Preclinical research examines GH-release activity and selectivity.
Pathway comparison — A different receptor target makes it useful for comparing secretagogue and GHRH signalling.
MOTS-c is a mitochondrial-derived peptide studied for cellular metabolic adaptation. Cell and mouse research explores AMPK-related signalling and how cells respond to metabolic stress.
Metabolic sensing — AMPK-related pathways connect cellular energy status with adaptive responses.
Stress signalling — Experiments investigate stress-responsive movement into the nucleus and changes in gene expression.
Mitochondrial communication — A peptide encoded within mitochondrial DNA offers a distinct perspective on communication within cells.
CJC-1295 with DAC engages the GHRH pathway; ipamorelin engages the ghrelin receptor. MOTS-c adds a separate lens on AMPK-related metabolic signalling and cellular stress. Their individual studies address different mechanisms, rather than a tested combined recovery effect.
Explore the evidence & study context
CJC-1295 with DAC
Human trial
Two randomized studies lasting 28 and 49 days reported sustained increases in GH and IGF-I after the long-acting CJC-1295 intervention.
These are hormone biomarkers, not performance or anti-ageing outcomes.
The stack contains separately labelled vials, not one combined mixture. A constituent such as GLOW or CJC/ipamorelin is itself a premixed blend, as named in the catalogue.
How is the price calculated?
The selected total is the sum of the current retail price of each constituent vial, multiplied by its displayed quantity. Two vials means two single-vial prices, not a bulk tier. No additional stack discount is applied.
Does adding this change a paid order?
No. The items enter your current demo bag together. Existing bag lines increase by their stated quantities; paid test orders remain unchanged. Checkout is simulated.
What handling information is available?
Format, strength and quantity are shown for each item. Storage, identity, purity and handling require verified batch-specific documentation. This collection supplies no dosing or cycle schedule.
Can component evidence prove the collection works?
No. Study findings retain their individual experimental context. A shared research theme does not establish the effects or safety of a combination.
Selank and Semax bring two complementary research questions into view: GABA-related signalling and neurotrophic pathways involved in learning and memory. A focused starting point for exploring stress-response and cognitive neuroscience.
Kisspeptin-10 and PT-141 place reproductive hormone signalling alongside melanocortin receptor biology. Explore why these distinct pathways attract interest in research on reproductive function and sexual-response signalling.